. 2022 Mar 28;2022:6483318. doi: 10.1155/2022/6483318

Table 4.

Patients with metastatic sentinel lymph nodes (m-SLNs).

Patient no.	No. of SLNs by SPECT/CT	m-SLN location	m-SLN radioactivity		Blue dye	ALND
Patient no.	No. of SLNs by SPECT/CT	m-SLN location	R _SPECT (%)	R _γ-probe (%)	Blue dye	ALND
1	1	L1	100	100	Negative	Yes
2	2	L1	100	100	Negative	No
3	2	L1	100	100	Negative	Yes
4	2	L1	100	100	Positive	Yes
4		L1	50^b	56^b	Negative	Yes
5	3	L1	100	100	Positive	Yes
6	2	L1	100	63^b	Negative	No
7	1	L1	100	100	Positive	Yes
8	0	L1	Fail	100	Negative	Yes
9	1	L1	100	100	Positive	Yes
10	3	L1	100	100	Positive	Yes
11	2	L1	100	100	Positive	No
12	2	L1	100	100	Positive	Yes
12		L1	Not	83^b	Positive	Yes
13	3	L1	100	100	Positive	Yes
13		L1	50^b	49^b	Positive	Yes
14	3	L1	97^b	100	Positive	No
15	4	L1	51^b	72^b	Positive	Yes
15		L1	48^c	41^c	Positive	Yes
15		L1	Not	Not	Negative	Yes
16	0	L1	Fail	100	Negative	Yes
17	1	L1	100	100	Positive	Yes
18	2	L1	100	100	Positive	Yes
18		L1	Not	10^f	Positive	Yes
19	1	L1	100	14^c	Negative	Yes
20	2	L1	100	100	Positive	Yes
21	3	L1	100	100	Positive	Yes
22	1	L1	100	25^b	Negative	Yes
23	3	L1	100	100	Positive	Yes

R _SPECT, R_γ-probe: the SLN was calculated as a percentage of the hottest node detected by SPECT/CT or γ-probe, and the hottest node detected by either modality was designated as 100%. ALND: axillary lymph node dissection. Fail: no lymph node detected on SPECT/CT. Not: palpable metastatic lymph nodes, which cannot be detected by SPECT/CT or γ-probe. b, c, f: second, third, fifth hottest node.